The polycythemia vera treatment market is currently undergoing a critical restructuring driven by pipeline innovation and patent risk. Polycythemia Vera (PV), a niche but high-value blood disorder segment, presents both high revenue opportunities and substantial competitive threats for pharmaceutical players in 2025.
JAKAFI: Dominance Under Scrutiny
JAKAFI (ruxolitinib) remains the...
English
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Tiếng Việt